# Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer

> **NCT06369259** · PHASE2 · RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 33 (estimated)

## Conditions studied

- Advanced Colorectal Cancer

## Interventions

- **DRUG:** Defactinib
- **DRUG:** Cetuximab
- **DRUG:** Avutometinib

## Key facts

- **NCT ID:** NCT06369259
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-24
- **Primary completion:** 2029-02-01
- **Final completion:** 2029-02-01
- **Target enrollment:** 33 (ESTIMATED)
- **Last updated:** 2026-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06369259

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06369259, "Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06369259. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*